Comparing the current results to its competitors, Avalo Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.74 %, recorded in the same quarter.
Avalo Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 187.15 %
Avalo Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical and biotechnology companies, academic and research institutions, and governmental agencies both in the United States and internationally. Competitors are developing pharmaceuticals targeting the same diseases and conditions as the company's research programs. Some competitors possess greater resources and more experience in research, development, and marketing. Additionally, competitors may have drugs in development or pending FDA approval that could reach the market before the company obtains approval for its products. Alternative therapies developed by competitors may also affect the market for the company's approved drugs. These competitors employ various technologies and methods, either different from or similar to those used by the company, to identify and validate drug candidates.
October 29, 2025
The therapeutic landscape for hidradenitis suppurativa (HS), a debilitating chronic inflammatory skin condition, has been markedly stagnant until recent advances in biotechnology. At the forefront of this change is Avalo Therapeutics, Inc., a clinical stage biotechnology firm that is striving to carve out a niche within a competitive market through its aggressive development of IL-1-based treatments for immune-mediated inflammatory diseases. The recent completion of patient enrollment in its Phase 2 LOTUS trial of AVTX-009 marks a significant milestone for the company. This article intends to evaluate the implications of this development in the context of Avalo s performance amidst various market dynamics a...
July 9, 2024
In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009. This development allows the biotechnology company to initiate its pivotal Phase 2 LOTUS clinical trial, aimed at exploring the efficacy of their anti-IL-1 monoclonal antibody (mAb) in mitigating this debilitating skin condition. Key Highlights: - IND Activation: The IND for AVTX-009 has been activated, paving the way for the commencement of Phase 2 clinical trials. - Target Disease - Hidradenitis Suppurativa (HS): HS is a chronic skin disease characterized by painful lumps and is notor...
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Avalo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Avalo Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
